Related references
Note: Only part of the references are listed.Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
Cloud P. Paweletz et al.
CLINICAL CANCER RESEARCH (2016)
Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer
Fumio Imamura et al.
LUNG CANCER (2016)
Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors
Yoshitaka Seki et al.
ONCOLOGIST (2016)
European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?
M. Malvezzi et al.
ANNALS OF ONCOLOGY (2015)
EGFR T790M resistance mutation in non small-cell lung carcinoma
Marc G. Denis et al.
CLINICA CHIMICA ACTA (2015)
Digital PCR analysis of circulating nucleic acids
Irena Hudecova
CLINICAL BIOCHEMISTRY (2015)
Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR
Masaru Watanabe et al.
CLINICAL CANCER RESEARCH (2015)
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony Mok et al.
CLINICAL CANCER RESEARCH (2015)
Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer
Guanshan Zhu et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Dynamic Plasma EGFR Mutation Status as a Predictor of EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Adenocarcinoma
Jeng-Sen Tseng et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
Kenneth S. Thress et al.
LUNG CANCER (2015)
Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer
Kai Guo et al.
ONCOTARGETS AND THERAPY (2015)
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
Priscilla K. Brastianos et al.
CANCER DISCOVERY (2015)
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
Niki Karachaliou et al.
JAMA ONCOLOGY (2015)
Considerations for Digital PCR as an Accurate Molecular Diagnostic Tool
Jim F. Huggett et al.
CLINICAL CHEMISTRY (2015)
Circulating Tumor DNA as a Liquid Biopsy for Cancer
Ellen Heitzer et al.
CLINICAL CHEMISTRY (2015)
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Reck et al.
ANNALS OF ONCOLOGY (2014)
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
J-Y Douillard et al.
BRITISH JOURNAL OF CANCER (2014)
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Epidermal growth factor receptor mutations in lung adenocarcinoma
Markus D. Siegelin et al.
LABORATORY INVESTIGATION (2014)
Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
Zhijie Wang et al.
PLOS ONE (2014)
Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer
Jan Nyrop Jakobsen et al.
EUROPEAN JOURNAL OF CANCER (2013)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Disease
Kadoaki Ohashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I-IV Non-Small Cell Lung Cancer Patients
Xiao Zhao et al.
RESPIRATION (2013)
A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry
Barbara Angulo et al.
PLOS ONE (2012)
High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number
Benjamin J. Hindson et al.
ANALYTICAL CHEMISTRY (2011)
New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer
Geoffrey R. Oxnard et al.
CLINICAL CANCER RESEARCH (2011)
Assessment of Epidermal Growth Factor Receptor and K-Ras Mutation Status in Cytological Stained Smears of Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcomes
Maria D. Lozano et al.
ONCOLOGIST (2011)
Quantitative Analysis of Tumor in Bronchial Biopsy Specimens
Caroline L. Coghlin et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers
Lynette M. Sholl et al.
CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: Impact of primary or secondary mutations
Akira Sakurada et al.
CLINICAL LUNG CANCER (2006)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
